Janux Rides Its TRACTr to Validation in Prostate Cancer and More Solid Tumors
A Janux Therapeutics T cell engager has early clinical data showing improvement in cases of advanced prostate cancer, validating the technology platform that produced the therapy. Janux is now leveraging its soaring stock price to raise $175 million in a stock offering.
Source: medcitynews.com